Multiple myeloma (MM) is a cancer that develops from the plasma cells of the bone marrow and accounts for ~1% of all cancers and
~10% of all hematological malignancies. US estimates for multiple myeloma incidence in 2017 are >30,000 new cases
diagnosed and approximately 12,500 deaths. The age adjusted incidence in the US is ~ 4 per 100,000 and, in the UK the value
is ~9 per 100,000. The worldwide incidence of multiple myeloma was >114,000 new cases in 2012.
Despite significant improvements in treatments including the use of immunomodulatory drugs (e.g. lenalidomide, pomalidomide)
and proteasome inhibitors (e.g. bortezomib, carfilzomib, ixazomib) in the first line setting, and the recent approvals for histone
deacetylase inhibitors (e.g. panobinostat) and monoclonal antibodies (daratumumab and elotuzumab), most patients eventually
relapse or are refractory and the management of the disease remains challenging.
Novel immunotherapeutic approaches in the treatment of multiple myeloma include checkpoint inhibitors, monoclonal antibodies,
vaccines and adoptive T-cell therapies. Chimeric Antigen Receptor (CAR-T) approaches are also being investigated by several
companies including Novartis, Kite/Gilead, Juno Therapeutics/Celgene, Bluebird therapeutics/Celgene, Legend
Biotech/J&J as well as several companies in early stage clinical investigations (Autolus, Poseida Therapeutics, Celyad).
This MarketVIEW product consists of a comprehensive Executive presentation (~110 slides, .pdf) detailing the disease
background, epidemiology of the disease, current therapies and treatment options, and novel immunotherapies with a focus on
CAR-T. Also included is a summary and analysis of published and registered ongoing CAR-T clinical studies detailing the
phases, targets under investigation, study status and summary of study protocols (patient numbers, dosing, study objectives).
Key significant data available to date is discussed in further detail. 122 references are cited in this work.
THIS PRODUCT IS A SUMMARY PRESENTATION (,pdf, 110 slides)